New Delhi Metallo-β-Lactamase, Ontario, Canada by Tijet, Nathalie et al.
LETTERS
New Delhi Metallo-
β-Lactamase, 
Ontario, Canada
To the Editor: The New Delhi 
metallo-β-lactamase (NDM-1) was 
ﬁ  rst characterized in 2009 from Kleb-
siella pneumoniae and Escherichia 
coli isolated from a patient in Sweden 
who had received medical care in New 
Delhi, India (1). Further studies have 
shown broad dissemination of this 
β-lactamase gene (blaNDM-1) in India, 
Pakistan, Bangladesh, and the United 
Kingdom (2). Additional isolates have 
been detected in other countries, and 
many of the patients with NDM-1–
producing Enterobacteriaceae report-
ed receiving medical care in the In-
dian subcontinent (1–7). We describe 
detection and characterization of an 
NDM-1–producing  K. pneumoniae 
isolated in Ontario, Canada.
In August 2010, a urinary tract 
infection was diagnosed in a 36-year-
old woman in a hospital in Brampton, 
Ontario. An E. coli strain sensitive to 
multiple antibacterial drugs (includ-
ing carbapenems) was isolated from 
a midstream urine sample; the patient 
was successfully treated with cipro-
ﬂ   oxacin. One week after treatment, 
when the patient did not have a fever 
or other clinical signs, a urine culture 
was repeated, and a carbapenem-resis-
tant K. pneumoniae isolate (GN529) 
was recovered. Travel history indi-
cated that the patient had recently re-
turned from India, where in mid-July 
she had had a miscarriage and had 
been hospitalized in Mumbai for 2 
days. At that time, no antimicrobial 
drug treatment was prescribed.
Susceptibility proﬁ  les of K. pneu-
moniae GN529 and its E. coli trans-
conjugant were obtained by using Etest 
(bioMérieux, Marcy l’Etoile, France) 
and the agar dilution method based on 
the Clinical and Laboratory Standards 
Institute guidelines (8). Multilocus 
sequence typing (MLST) of isolate 
GN529 was performed as described 
(9). The Pasteur Institute online data-
base (www.pasteur.fr/recherche/geno-
pole/PF8/mlst/Kpneumoniae.html) 
was used to assign the allelic numbers 
and sequence type (ST).
To screen for the most commonly 
known β-lactamase genes in enterobac-
teria, we performed multiplex PCRs 
(10). Primers were designed (NDM-
F, 5′-AATGGAATTGCCCAATATT
ATGC-3′; NDM-R, 5′-CGAAAGTCA
GGCTGTGTTG C-3′) for the speciﬁ  c 
detection of blaNDM-1 and included in 
1 of the multiplex PCRs (multiplex 
V). Primers NDM-F and NDM-R2 
(5′-TCAGCGCAGCTTGTCGGC-3′) 
were used to amplify and sequence the 
entire blaNDM-1 gene. The samples were 
screened for the presence of six 16S 
methylase genes (armA, rmtA–D, and 
npmA) by PCR. E. coli J53 transcon-
jugants were selected on Luria-Bertani 
plates containing sodium azide and 
meropenem (100 μg/mL and 1 μg/mL, 
respectively). The plasmid harboring 
blaNDM-1 was identiﬁ  ed by Southern blot 
analysis by using a speciﬁ  c digoxigen-
in-labeled blaNDM-1 probe (Roche Diag-
nostics, Indianapolis, IN, USA).
K. pneumoniae GN529 was highly 
resistant to all β-lactams, aminoglyco-
sides, quinolones, tetracycline, nitrofu-
rantoin, and co-trimoxazole. MICs of 
0.5 μg/mL for colistin (European Com-
mittee on Antimicrobial Susceptibility 
Testing colistin breakpoint for Entero-
bacteriaceae: susceptibility <2 μg/mL) 
and 1 μg/mL for tigecycline (European 
Committee on Antimicrobial Suscepti-
bility Testing and US Food and Drug 
Administration tigecycline breakpoint 
for  Enterobacteriaceae: susceptibility 
<1 and <2 μg/mL, respectively) were 
also obtained (Table).
Considering the travel history 
of the patient and the high level re-
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Table. Antibacterial drug susceptibility profiles and resistance genes of Klebsiella
pneumoniae GN529 clinical isolate and its Escherichia  coli transconjugant, Ontario, 
Canada, 2010* 
Antibacterial drug or gene 
MIC, ȝg/mL 
Kpn GN529  Eco J529  Eco J53 
Ampicillin >256 >256 6 
Cefoxitin >256 >256 8 
Ceftazidime >256 >256 0.19 
Cefotaxime >256 >256 0.094 
Cefepime 48  48  0.064 
Ertapenem 32  12  0.008 
Meropenem >32 4  0.023 
Imipenem >32 32  0.38 
Amikacin >256 >256 1.5 
Gentamicin >256 >256 1.5 
Tobramycin >256 >256 1 
Ciprofloxacin >32 0.012  0.012 
Tetracycline >16 0.78 1 
Tigecycline 1  ND  ND 
Nitrofurantoin >512 ND  ND 
Colistin 0.5  ND  ND 
Co-trimoxazole 4/76  ND  ND 
PCR† and sequencing       
  blaNDM-1 +  +  ND 
  blaCTX-M-15 +    ND 
  blaSHV-12 +  +  ND 
  blaSHV-11 +  –  ND 
  blaOXA-1 +  –  ND 
  blaTEM-1 +  –  ND 
  armA  + +  ND 
*Kpn, Klebsiella pneumoniae; Eco J529, Escherichia coli transconjugant strain; Eco J53, recipient E.
coli J53; ND, not determined. 
†PCR screening included blaTEM, blaSHV, blaOXA-1-like, blaCTX-M groups 1, 2, and 9, blaVEB, blaPER, 
blaGES, blaOXA-48-like, blaIMP, blaVIM, blaKPC, blaNDM-1, and 6 groups of blaAmpC genes. LETTERS
sistance to all β-lactams, molecular 
screening of β-lactamases in strain 
GN529 was initiated to identify pos-
sible carbapenemases (e.g., blaNDM-1) 
in that isolate. Five β-lactamases 
genes (blaNDM, blaSHV, blaTEM, group 1 
blaCTX-M , and blaOXA) and one 16S 
rRNA methylase (armA) were de-
tected. By using primers for ampliﬁ  -
cation of complete genes, we obtained 
sequences of blaNDM-1, 2 extended-
spectrum  β-lactamases (blaCTX-M-15 
and  blaSHV-12), 3 broad-spectrum 
β-lactamases (blaSHV-11,  blaTEM-1 and 
blaOXA-1), and methyltransferase armA. 
No AmpC β-lactamases were linked 
to this isolate. Southern blotting iden-
tiﬁ  ed a plasmid of ≈150 kb harboring 
blaNDM-1 (data not shown). A trans-
conjugant E. coli positive for blaNDM-1 
(E. coli J529, Table) was resistant to all 
β-lactams and aminoglycosides tested. 
In addition, blaSHV-12 and armA were 
detected in strain J529 (Table), indi-
cating the potential for the horizontal 
spread of these resistance genes.
K. pneumoniae GN529 was typed 
by MLST as ST147, the same type as 
a clinical NDM-1–producing strain 
isolated in Australia (6) but distinct 
from ST14 and ST16 strains described   
(1,7). There are insufﬁ  cient  MLST 
data to conﬁ  rm polyclonal dissemina-
tion of NDM-1, but previous pulsed-
ﬁ  eld gel electrophoresis results sup-
port that hypothesis (2).
K. pneumoniae GN529 was iso-
lated from a patient who had recently 
received emergency medical care in 
India, suggesting importation of this 
clinical strain. In the United Kingdom, 
where Enterobacteriaceae containing 
blaNDM-1 are increasingly common, 
carriage of these organisms has been 
closely linked to receipt of medical 
care in the Indian subcontinent (2). 
Similar association as a risk factor 
was observed in other regions, includ-
ing  blaNDM-1-positive clinical strains 
isolated in North America, Australia, 
and Africa (3–6,10).
The NDM-1–producing entero-
bacteria described in this study previ-
ously had low MICs only for colistin 
and tigecycline (1,2,5,6). However, an 
NDM-1 isolate resistant to these anti-
microbial drugs has also been described 
(2). Early detection and implementa-
tion of infection control interventions 
is essential for preventing the spread 
of multidrug-resistant organisms such 
as these. It may be prudent to con-
sider medical exposure in the Indian 
subcontinent as a risk factor for pos-
sible infection, colonization, or both 
with multidrug-resistant, NDM-1–
producing Enterobacteriaceae.
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